Skip to content

Advertisement

  • Poster presentation
  • Open Access

Mass-production of human dendritic cells in accordance with gmp for clinical studies

  • 1,
  • 1 and
  • 2
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P207

https://doi.org/10.1186/2051-1426-3-S2-P207

Published: 4 November 2015

Keywords

  • Dendritic Cell
  • Peripheral Blood Mononuclear Cell
  • Cancer Immunotherapy
  • Good Manufacture Practice
  • Human Dendritic Cell

Background

Although clinical studies have established that antigen-loaded dendritic cells (DCs) vaccines are safe and promising therapy for various kinds of malignancies, their clinical efficacy remains to be established. Issues that limit the clinical efficacy of DC-based immunotherapy, as well as the difficulty of the industrial production of DCs, are largely due to the limited number of autologous DCs available from each patient (Kato T., et al. Neoplasia 2010), and it is necessary to prepare an enough number of DCs for effective treatments of tumors. In this study, therefore, we attempted to expand functional human DCs of cancer patients ex vivo.

Methods

The method to produce DCs, prepared in accordance with Good Manufacturing Practice (GMP) guidelines, is an optimization of ex vivo preparation method for generating large numbers of DCs from peripheral blood mononuclear cells (PBMCs) obtained by leukapheresis for clinical studies. Several fraction-depleted PBMCs were expanded and differentiated into DCs in the presence of optimal cytokine cocktails for 3-4 weeks by floating cultivation.

Results

By this method, about 1x109 CD11c+ cells could be obtained. These cells had typical features (endocytotic activity, expression of HLA-DR, adhesion molecules, chemokine receptor and co-stimulatory molecules, production of inflammatory cytokines, allo-MLR activity and positive for tetramer assay) of conventional myeloid DCs in vitro. Therefore, the concept of DC expansion should contribute significantly to the progress of DC immunotherapy.

Conclusions

We established a new culture method to expand human DCs. Expanded DCs had properties that were required to obtain therapeutic gain. Thus, we expect that this technology will improve therapeutic gain of cancer and alleviate patients' burden of apheresis, and be able to contribute largely to both basic and clinical research of human cancer immunotherapy.

Authors’ Affiliations

(1)
R&D Laboratory for innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Fukuoka, Japan
(2)
R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan

Copyright

© Harada et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement